JP2020536098A - グリシン脳症を治療するためのベンゾエート含有組成物の使用 - Google Patents

グリシン脳症を治療するためのベンゾエート含有組成物の使用 Download PDF

Info

Publication number
JP2020536098A
JP2020536098A JP2020519254A JP2020519254A JP2020536098A JP 2020536098 A JP2020536098 A JP 2020536098A JP 2020519254 A JP2020519254 A JP 2020519254A JP 2020519254 A JP2020519254 A JP 2020519254A JP 2020536098 A JP2020536098 A JP 2020536098A
Authority
JP
Japan
Prior art keywords
patient
glyceryl
pharmaceutical composition
formulation
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020519254A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536098A5 (https=
Inventor
パハン，カリパダ
Original Assignee
ラッシュ・ユニバーシティ・メディカル・センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラッシュ・ユニバーシティ・メディカル・センター filed Critical ラッシュ・ユニバーシティ・メディカル・センター
Publication of JP2020536098A publication Critical patent/JP2020536098A/ja
Publication of JP2020536098A5 publication Critical patent/JP2020536098A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020519254A 2017-10-06 2018-09-26 グリシン脳症を治療するためのベンゾエート含有組成物の使用 Pending JP2020536098A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762569251P 2017-10-06 2017-10-06
US62/569,251 2017-10-06
PCT/US2018/052879 WO2019070478A1 (en) 2017-10-06 2018-09-26 USE OF A BENZOATE-CONTAINING COMPOSITION FOR TREATING GLYCINIC ENCEPHALOPATHY

Publications (2)

Publication Number Publication Date
JP2020536098A true JP2020536098A (ja) 2020-12-10
JP2020536098A5 JP2020536098A5 (https=) 2021-08-12

Family

ID=65994915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020519254A Pending JP2020536098A (ja) 2017-10-06 2018-09-26 グリシン脳症を治療するためのベンゾエート含有組成物の使用

Country Status (10)

Country Link
US (1) US11304923B2 (https=)
EP (1) EP3691630A4 (https=)
JP (1) JP2020536098A (https=)
KR (1) KR20200065012A (https=)
CN (1) CN111212637A (https=)
AU (2) AU2018345244A1 (https=)
BR (1) BR112020005856A2 (https=)
CA (1) CA3078609A1 (https=)
EA (1) EA202090666A1 (https=)
WO (1) WO2019070478A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020176432A1 (en) * 2019-02-25 2020-09-03 Rush University Medical Center Compositions including cinnamic acid and methods of use thereof
AU2020315331A1 (en) 2019-07-16 2022-02-03 Rush University Medical Center Use of a benzoate containing composition to treat neurodegenerative disorders
CN116390761A (zh) 2020-10-28 2023-07-04 拉什大学医学中心 肉桂酸苄酯组合物在治疗甘氨酸脑病和尿素循环障碍中的应用
CA3205005A1 (en) * 2020-12-16 2022-06-23 Rush University Medical Center Administration of glycerol tribenzoate and glycerol phenylbutyrate for treatment of neurodegenerative and urea cycle disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015509489A (ja) * 2012-02-10 2015-03-30 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ がんの処置のためのグリシン開裂系の阻害
JP2017505811A (ja) * 2014-01-17 2017-02-23 ラッシュ・ユニバーシティ・メディカル・センター 尿素サイクル障害及び神経変性障害におけるベンゾエート含有組成物の使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015509489A (ja) * 2012-02-10 2015-03-30 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ がんの処置のためのグリシン開裂系の阻害
JP2017505811A (ja) * 2014-01-17 2017-02-23 ラッシュ・ユニバーシティ・メディカル・センター 尿素サイクル障害及び神経変性障害におけるベンゾエート含有組成物の使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COMPREHENSIVE REVIEWS IN FOOD SCIENCE AND FOOD SAFETY, vol. 16, JPN6022029402, 2017, pages 868 - 880, ISSN: 0004995495 *
J. INHERIT. METAB. DIS., vol. 28, JPN6022029400, 2005, pages 651 - 663, ISSN: 0004995496 *

Also Published As

Publication number Publication date
KR20200065012A (ko) 2020-06-08
CN111212637A (zh) 2020-05-29
EA202090666A1 (ru) 2020-08-05
US20200281884A1 (en) 2020-09-10
EP3691630A4 (en) 2021-10-27
US11304923B2 (en) 2022-04-19
CA3078609A1 (en) 2019-04-11
AU2018345244A1 (en) 2020-04-02
BR112020005856A2 (pt) 2020-09-29
EP3691630A1 (en) 2020-08-12
AU2022200277A1 (en) 2022-02-03
WO2019070478A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
CA2498260C (en) Pharmaceutical formulations of modafinil
US12478598B2 (en) Compositions including cinnamic acid and methods of use thereof
AU2022200277A1 (en) The use of a benzoate containing composition to treat glycine encephalopathy
JP6836905B2 (ja) 尿素サイクル障害及び神経変性障害におけるベンゾエート含有組成物の使用
KR101734152B1 (ko) 신경계 장애의 치료를 위한 아세토아세테이트의 모노글리세리드 및 유도체
JPH0761923A (ja) アルツハイマー病治療剤
KR20080005335A (ko) 치료제
WO2022093922A1 (en) Use of a cinnamein composition for the treatment of glycine encephalopathy and urea cycle disorders
WO2001012200A1 (en) An oral composition comprising coenzyme a for treating hyperlipemia, the preparation method and the use thereof
JP6454436B1 (ja) ペマフィブラートを含有する医薬
US6890941B1 (en) Compositions containing HMG Co-A reductase inhibitors and policosanol
CN117919216A (zh) 2-羟基-3-甲基丁酸在制备预防和/或治疗动脉粥样硬化的药物中的应用
US20200138776A1 (en) Composition for use in the treatment of endometriosis and symptoms associated with endometriosis
TWI920601B (zh) 降低血脂之組合物及其用途
CN110585182A (zh) 双硫仑在制备治疗和预防高血脂药物或动脉粥样硬化药物中的用途
CN110327340A (zh) 培氟沙星在制备治疗和预防高血脂药物或动脉粥样硬化药物中的用途
CN112451678B (zh) HMG-CoA还原酶抑制剂-维D的药物组合物及用途
EP4098254A1 (en) Cannabidiol for use in the treatment of pain resulting from an indoleamine 2,3-dioxygenase-1 (ido1) related disease
TW202547551A (zh) 降低血脂之組合物及其用途
JP2007137896A (ja) イブプロフェン含有医薬製剤
MX2014002965A (es) Combinaciones que comprenden un modulador del receptor de s1p.
CN112426530A (zh) 他汀组合物及其在制备抑制肌毒性的降脂药物中的用途
ZA200502789B (en) Pharmaceutical formulations of modafinil
KR20200140326A (ko) 락티톨 및 비알코올성 지방간 질병을 위한 경구용 약제학적 형태
JP2008056701A (ja) イブプロフェン含有医薬製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210701

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220719

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230221